Housemarks. Each Party acknowledges the goodwill and reputation that has been associated with the other Party’s Housemarks over the years, and shall use such Housemarks in a manner that maintains and promotes such goodwill and reputation and is consistent with trademark guidelines. Each Party shall take all reasonable precautions and actions to protect the goodwill and reputation that has inured to the other Party’s Housemarks, shall refrain from doing any act that is reasonably likely to impair the reputation of such Housemarks, and shall cooperate fully to protect such Housemarks.
Housemarks. Each Party shall enter into appropriate licenses and covenants in respect of its or its Affiliates' use of the other Party's Housemarks at such time as the Joint Steering Committee determines prior to Commercialization of the applicable Alliance Product. Such licenses shall ensure that each Party acknowledges the goodwill and reputation that has been associated with the other Party's Housemarks over the years, and shall use such Housemarks in a manner that maintains and promotes such goodwill and reputation and is consistent with trademark guidelines. Further, such licenses shall ensure that each Party shall take all reasonable precautions and actions to protect the goodwill and reputation that has inured to the other Party's Housemarks, shall refrain from doing any act that is reasonably likely to impair the reputation of such Housemarks, and shall cooperate fully to protect such Housemarks.
Housemarks. Licensee will be responsible for the registration and maintenance of the Licensee Housemarks throughout the Territory, as well as all expenses associated therewith. Akebia will be responsible for the registration and maintenance of the Akebia Housemarks throughout the Territory, as well as all expenses associated therewith. Article XI INFORMATION; PHARMACOVIGILANCE;
Housemarks. Neither Party shall, and shall ensure that its Affiliates and sublicensees will not, make any use of the trademarks or house marks of the other Party or its Affiliates or licensees (including their corporate names) or any trademark confusingly similar thereto. *** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission.
Housemarks. Neither Party shall, and shall ensure that its Affiliates and sublicensees will not, make any use of the trademarks or house marks of the other Party or its Affiliates or licensees (including their corporate names) or any trademark confusingly similar thereto.
Housemarks. Each Party acknowledges the goodwill and reputation that has been associated with the other Party’s Housemarks over the years, and shall use such Housemarks in a manner that maintains and promotes such goodwill and reputation and is consistent with the owner’s trademark guidelines. In using the other Party’s Housemarks (and, with respect to THERAVANCE, the MYLAN Product Trademarks) pursuant to the licenses granted in Sections 2.01 and 2.02 above, each Party shall (i) take reasonable precautions and actions to protect the goodwill and reputation that has inured to the other Party’s Housemarks and MYLAN Product Trademarks, and (ii) refrain from doing any act that is intended, and use Diligent Efforts to refrain from doing any act that is reasonably likely, to impair the reputation of such Housemarks and MYLAN Product Trademarks. ***CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.
Housemarks. Licensee will Commercialize the Licensed Products only under the applicable Product Marks and each Party’s Housemarks as set forth herein, and no other Marks.
Housemarks. The Parties, through the JSC, in consultation with regulatory experts, will [***].
Housemarks. As soon as reasonably practicable in Amgen’s normal course of business after the Restated Effective Date but in no event longer than [***] after the Restated Effective Date, the Novartis Housemarks shall be removed from the electronic formats of the Novartis Branded Materials and Amgen will not print any new Promotional Materials that includes the Novartis Housemarks any later than [***] after the Restated Effective Date. After the Housemark Transition Period, Amgen shall have no right to use any Novartis Housemarks; provided, for clarity, (a) Amgen shall have the right to produce inventory of Product packaging and labeling materials bearing the Novartis Housemarks for up to [***] following the Restated Effective Date and (b) to the extent Product packaging and labeling is already in distribution channels at the conclusion of the Housemark Transition Period, Novartis authorizes the continued use of such Novartis Housemarks on or within such Product packaging and labeling in such distribution channels.
Housemarks. Promotional Materials and all packaging and package inserts for the Product in the Field in the United States will display the Novartis Housemarks and the Amgen Housemarks in equal prominence to the extent allowed by applicable Law and in accordance with the applicable Commercialization Plan, and to the extent reasonably practicable; provided that, in the event that it is not reasonably practicable to display the Novartis Housemarks on any packaging or package inserts, the Parties shall discuss such matter, and the Novartis Housemarks shall be displayed as soon as reasonably practicable. Except for the use of the Novartis Housemarks and the Amgen Housemarks as may be expressly set forth in the applicable Commercialization Plan, each Party will promote the Product in the Field in the United States only under the Novartis Product Trademarks or Amgen Product Trademarks, as applicable.
